News & Updates
Filter by Specialty:
Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
In patients with chronic hepatitis B (CHB), treatment with the small interfering RNA JNJ-3989, in combination with a nucleos(t)ide analogue (NA), safely reduces levels of the hepatitis B surface antigen (HBsAg) for up to almost a year after the last dose, a new study has found.
Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
03 Aug 2022
Do cardiovascular drugs worsen COVID-19 outcomes?
Cardiovascular medications, such as angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blocker (ARBs) and anticoagulants, do not induce poor clinical outcomes in patients with COVID-19 and thus should not be discontinued, suggest the results of a meta-analysis.
Do cardiovascular drugs worsen COVID-19 outcomes?
03 Aug 2022
GLP-1 RAs help lower serum uric acid concentration
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a drug class mainly used for the management of type 2 diabetes, significantly reduces serum uric acid (SUA) concentration, a recent study has shown.
GLP-1 RAs help lower serum uric acid concentration
03 Aug 2022
Cognition assessment important to ensure patient adherence to MS therapy
Adherence to disease-modifying therapies (DMT) in multiple sclerosis (MS) is dependent not only on the properties of the medications themselves, but also on the capacities of the patient, a recent study has found.